Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 Y375C |
| Therapy | Futibatinib |
| Indication/Tumor Type | intrahepatic cholangiocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 Y375C | intrahepatic cholangiocarcinoma | predicted - sensitive | Futibatinib | Case Reports/Case Series | Actionable | In a clinical case study, Lytgobi (futibatinib) treatment resulted in a partial response with a progression-free survival of 35.5 months and a best objective response of -45% in a patient with intrahepatic cholangiocarcinoma harboring FGFR2 Y375C (reported as Y376C) (PMID: 39226398). | 39226398 |
| FGFR2 Y375C | intrahepatic cholangiocarcinoma | predicted - sensitive | Futibatinib | Case Reports/Case Series | Actionable | In a Phase I trial, Lytgobi (futibatinib) treatment resulted in an objective response rate (ORR) of 7.3% (6/82, all partial responses(PR)) and a disease control rate of 32.9% (27/82) in patients with advanced solid tumors overall, and an ORR of 11.5% (6/52, all PR) and DCR of 36.5% (19/52) with FGF/FGFR abnormalities, including a partial response in a patient with intrahepatic cholangiocarcinoma harboring FGFR2 Y375C (PMID: 35838190). | 35838190 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39226398) | Understanding and Overcoming Resistance to Selective FGFR inhibitors Across FGFR2-Driven Malignancies. | Full reference... |
| (35838190) | Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors. | Full reference... |